vs
Side-by-side financial comparison of FIRST HAWAIIAN, INC. (FHB) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $220.3M, roughly 1.3× FIRST HAWAIIAN, INC.). FIRST HAWAIIAN, INC. runs the higher net margin — 30.8% vs 12.8%, a 17.9% gap on every dollar of revenue. Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs 3.8%).
First Hawaiian, Inc. is a bank holding company headquartered in Honolulu, Hawaiʻi. Its principal subsidiary, First Hawaiian Bank, founded in 1858, is Hawaiʻi’s oldest and largest financial institution headquartered in Honolulu at the First Hawaiian Center. The bank has 57 branches throughout Hawaiʻi, three in Guam and one in Saipan. It offers banking services to consumer and commercial customers, including deposit products, lending services and wealth management, insurance, private banking an...
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
FHB vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $220.3M | $295.9M |
| Net Profit | $67.8M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | — | 18.4% |
| Net Margin | 30.8% | 12.8% |
| Revenue YoY | — | -6.4% |
| Net Profit YoY | 14.4% | 68.3% |
| EPS (diluted) | $0.55 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $220.3M | — | ||
| Q4 25 | $225.9M | $295.9M | ||
| Q3 25 | $226.4M | — | ||
| Q2 25 | $217.5M | $317.0M | ||
| Q1 25 | $211.0M | $316.2M | ||
| Q4 24 | $188.1M | $297.0M | ||
| Q3 24 | $210.0M | $289.5M | ||
| Q2 24 | $204.6M | $306.1M |
| Q1 26 | $67.8M | — | ||
| Q4 25 | $69.9M | $38.0M | ||
| Q3 25 | $73.8M | — | ||
| Q2 25 | $73.2M | $-17.7M | ||
| Q1 25 | $59.2M | $22.6M | ||
| Q4 24 | $52.5M | $34.9M | ||
| Q3 24 | $61.5M | $33.6M | ||
| Q2 24 | $61.9M | $40.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | — | — | ||
| Q4 25 | 41.2% | 18.4% | ||
| Q3 25 | 42.5% | — | ||
| Q2 25 | 40.5% | -7.5% | ||
| Q1 25 | 36.5% | 12.2% | ||
| Q4 24 | 34.4% | 16.0% | ||
| Q3 24 | 36.4% | 13.8% | ||
| Q2 24 | 39.5% | 15.0% |
| Q1 26 | 30.8% | — | ||
| Q4 25 | 31.0% | 12.8% | ||
| Q3 25 | 32.6% | — | ||
| Q2 25 | 33.7% | -5.6% | ||
| Q1 25 | 28.1% | 7.1% | ||
| Q4 24 | 27.9% | 11.7% | ||
| Q3 24 | 29.3% | 11.6% | ||
| Q2 24 | 30.3% | 13.3% |
| Q1 26 | $0.55 | — | ||
| Q4 25 | $0.56 | $0.24 | ||
| Q3 25 | $0.59 | — | ||
| Q2 25 | $0.58 | $-0.11 | ||
| Q1 25 | $0.47 | $0.14 | ||
| Q4 24 | $0.41 | $0.22 | ||
| Q3 24 | $0.48 | $0.21 | ||
| Q2 24 | $0.48 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $172.9M |
| Total DebtLower is stronger | $0 | $260.0M |
| Stockholders' EquityBook value | $2.8B | $2.0B |
| Total Assets | $24.3B | $2.5B |
| Debt / EquityLower = less leverage | 0.00× | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $172.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $162.2M | ||
| Q1 25 | — | $140.7M | ||
| Q4 24 | — | $177.5M | ||
| Q3 24 | — | $187.5M | ||
| Q2 24 | — | $152.9M |
| Q1 26 | $0 | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $2.0B | ||
| Q3 25 | $2.7B | — | ||
| Q2 25 | $2.7B | $1.9B | ||
| Q1 25 | $2.6B | $2.0B | ||
| Q4 24 | $2.6B | $2.1B | ||
| Q3 24 | $2.6B | $2.1B | ||
| Q2 24 | $2.6B | $2.1B |
| Q1 26 | $24.3B | — | ||
| Q4 25 | $24.0B | $2.5B | ||
| Q3 25 | $24.1B | — | ||
| Q2 25 | $23.8B | $2.6B | ||
| Q1 25 | $23.7B | $2.6B | ||
| Q4 24 | $23.8B | $2.7B | ||
| Q3 24 | $23.8B | $2.7B | ||
| Q2 24 | $24.0B | $2.7B |
| Q1 26 | 0.00× | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FHB
| Net Interest Income | $167.5M | 76% |
| Noninterest Income | $52.8M | 24% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
